Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 8.8 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 8/2008

Patients: This phase III study 410 patients with metastatic renal cell carcinoma (kidney cancer). They ranged in age from 27 to 85 years. The majority (77%) of these patients were men.

Treatment: Patients were treated with either everolimus (a biological therapy) placebo (a substance that looks like the active study drug but does not have any effect).

Toxicity: Grade 4 leuokopenia and thrombocytopenia were each reported in one patient in the placebo group. In the everolimus treated group, three patients had grade 4 infections, one had grade 4 anemia, and four had grade 4 lymphopenia. Grade 3 toxicities in the everolimus treatment group included stomatitis, rash, fatigue, asthenia, diarrhea, anorexia, mucosal inflammation, dry skin, infections, pneumonitis, dyspnea, anemia, and laboratory abnormalities. Each of these grade 3 events (other than the laboratory abnormalities) occurred in less than 5% of patients.

Results: The median overall survival was 8.8 months for the placebo group, and had not yet been reached for the everolimus-treated patients.

Support: This study was supported by research funds from Novartis, which developed everolimus.

Correspondence: Dr. Robert Motzer

E-mail to a Friend Email Physician More Information